1352805-02-7

Basic information

• Product Name: 4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)pyrimidine-5-carboxylic acid
• Synonyms: 4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)pyrimidine-5-carboxylic acid
• CAS NO: 1352805-02-7
• Molecular Weight: 356.768
• Mol File: 1352805-02-7.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)pyrimidine-5-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)pyrimidine-5-carboxylic acid(1352805-02-7)
• EPA Substance Registry System: 4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)pyrimidine-5-carboxylic acid(1352805-02-7)

Safety Data

• Hazardous Substances Data: 1352805-02-7(Hazardous Substances Data)

Upstream product

• 524955-09-7 3-chloro-4-(2-pyridylmethoxy)aniline 
• 1328624-09-4 ethyl 4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)pyrimidine-5-carboxylate 
• 41103-17-7 ethyl 4-chloropyrimidine-5-carboxylate 
• 4786-52-1 ethyl 4-hydroxypyrimidine-5-carboxylate 

Downstream Products

• 1328624-10-7 methyl 2-((4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)pyrimidin-5-carbnyl)amino)-3-hydroxypropanoate 
• 1328624-11-8 methyl 2-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)pyrimidin-5-yl)-4,5-dihydrooxazole-4-carboxylate 
• 1328624-13-0 (2-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)pyrimidin-5-yl)oxazol-4-yl)methanol 
• 1328624-14-1 (5-(4-aminomethyloxazol-2-yl)pyrimidin-4-yl)-(3-chloro-(pyridin-2-ylmethoxy)phenyl)amine 
• 1328624-08-3 N-((2-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)pyrimidin-5-yl)oxazol-4-yl)methyl)acrylamide 
• 1328624-12-9 methyl 2-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)pyrimidin-5-yl)oxazole-4-carboxylate 

Relevant articles and documents

Synthesis and biological evaluation of pyrimidine-based dual inhibitors of human epidermal growth factor receptor 1 (HER-1) and HER-2 tyrosine kinases

A novel series of N4-(3-chlorophenyl)-5-(oxazol-2-yl)pyrimidine- 4,6-diamines were synthesized and evaluated as dual inhibitors of HER-1/HER-2 tyrosine kinases. In contrast to the currently approved HER-2-targeted agent (lapatinib, 1), our irreversible HER-1/HER-2 inhibitors have the potential to overcome the clinically relevant and mutation-induced drug resistance. The selected compound (19a) showed excellent inhibitory activity toward HER-1/HER-2 tyrosine kinases with selectivity over 20 other kinases and inhibited the proliferation of both cancer cell types: lapatinib-sensitive cell lines (SK-Br3, MDA-MB-175, and N87) and lapatinib-resistant cell lines (MDA-MB-453, H1781, and H1975). The excellent pharmacokinetic profiles of 19a in mice and rats led us to further investigation of a novel therapeutic agent for HER-2-targeting treatment of solid tumors, especially HER-2-positive breast/gastric cancer and HER-2-mutated lung cancer.